Abstract: FASEB BioAdvances
RESEARCH ARTICLE
OPEN ACCESS
Oral MIB-626 (β Nicotinamide Mononucleotide) Safely
Raises Blood Nicotinamide Adenine Dinucleotide Levels
in Hospitalized Patients With COVID-19 and Acute Kidney
Injury: A Randomized Controlled Trial
Karol M. Pencina1 | David E. Leaf 2 | Rodrigo J. Valderrabano1 | Sushrut S. Waikar3 | Tapan S. Mehta4 | Yili Valentine Shang1 |
Nancy K. Latham1 | Tejossy John4 | Elena Volpi5 | Dahlene Fusco6 | Yusnie Memish-Beleva1 | Shobana Krishnamurthy2 |
Siva Lavu7 | Salma Karmi7 | David J. Livingston7 | Shalender Bhasin1
1Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's
Hospital, Harvard Medical School, Boston, Massachusetts, USA | 2Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts,
USA | 3Department of Medicine, Section of Nephrology, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston,
Massachusetts, USA | 4Department of Family and Community Medicine, University of Alabama, Birmingham, Alabama, USA | 5University of Texas
Medical Branch, Galveston, Texas, USA | 6Tulane University School of Medicine, New Orleans, Louisiana, USA | 7 Metro International Biotech, Worcester,
Massachusetts, USA
Correspondence: Shalender Bhasin (sbhasin@bwh.harvard.edu)
Received: 16 January 2025 | Revised: 10 March 2025 | Accepted: 31 March 2025
Funding: The trial was funded by Metro International Biotech LLC. Drs. Bhasin and Pencina were partially supported by the Boston Claude D. Pepper
Older Americans Independence Center (National Institute on Aging grant 5P30AG31679).
Keywords: acute kidney injury | COVID-19 | NAD augmentation | NAD metabolism | NAD precursor | nicotinamide mononucleotide
ABSTRACT
Nicotinamide adenine dinucleotide (NAD+) plays an important role in the innate immune response and is depleted during SARS-
CoV-2 infection due to increased turnover. It is unknown whether treatment with NAD+ precursors can safely raise NAD+ levels
in patients with COVID-19. To determine whether MIB-626 (β-nicotinamide mononucleotide), an NAD+ precursor, can safely increase blood NAD+ levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID-19, 42
adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice
daily for 14 days. Circulating NAD+ and its metabolites, markers of AKI, inflammation, and disease severity, were assessed.
MIB-626 treatment significantly but gradually raised blood NAD+ levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6,
and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14) and raised plasma concentrations of NAD+ metabolites 1-methylnicotinamide,
N-methyl, 2-pyridone, 4-carboxamide rapidly to a peak by day 3. Changes in serum creatinine, cystatin-C, and serum markers of
AKI did not differ significantly between groups. Serum CRP, IL-6, and TNFα and indices of disease severity also did not differ
between groups. MIB-626 treatment of patients with COVID-19 and AKI safely and substantially raised blood NAD+ and plasma
concentrations of NAD+ metabolites. Markers of AKI, inflammation, and disease severity did not differ between groups, likely
due to the slow rise in NAD+ levels. Future studies should assess whether a rapid increase in NAD+ by parenteral administration
can attenuate disease severity and AKI.
Trial..
DOI record:
{
"DOI": "10.1096/fba.2025-00014",
"ISSN": [
"2573-9832",
"2573-9832"
],
"URL": "http://dx.doi.org/10.1096/fba.2025-00014",
"abstract": "<jats:title>ABSTRACT</jats:title>\n <jats:p>\n Nicotinamide adenine dinucleotide (NAD\n <jats:sup>+</jats:sup>\n ) plays an important role in the innate immune response and is depleted during SARS‐CoV‐2 infection due to increased turnover. It is unknown whether treatment with NAD\n <jats:sup>+</jats:sup>\n precursors can safely raise NAD\n <jats:sup>+</jats:sup>\n levels in patients with COVID‐19. To determine whether MIB‐626 (\n <jats:italic>β‐</jats:italic>\n nicotinamide mononucleotide), an NAD\n <jats:sup>+</jats:sup>\n precursor, can safely increase blood NAD\n <jats:sup>+</jats:sup>\n levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID‐19, 42 adults, ≥ 18 years, hospitalized with COVID‐19 and AKI, were randomized in a 3:2 ratio to MIB‐626 1.0‐g or placebo tablets twice daily for 14 days. Circulating NAD\n <jats:sup>+</jats:sup>\n and its metabolites, markers of AKI, inflammation, and disease severity, were assessed. MIB‐626 treatment significantly but gradually raised blood NAD\n <jats:sup>+</jats:sup>\n levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6, and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14) and raised plasma concentrations of NAD\n <jats:sup>+</jats:sup>\n metabolites 1‐methylnicotinamide, N‐methyl, 2‐pyridone, 4‐carboxamide rapidly to a peak by day 3. Changes in serum creatinine, cystatin‐C, and serum markers of AKI did not differ significantly between groups. Serum CRP, IL‐6, and TNFα and indices of disease severity also did not differ between groups. MIB‐626 treatment of patients with COVID‐19 and AKI safely and substantially raised blood NAD\n <jats:sup>+</jats:sup>\n and plasma concentrations of NAD\n <jats:sup>+</jats:sup>\n metabolites. Markers of AKI, inflammation, and disease severity did not differ between groups, likely due to the slow rise in NAD\n <jats:sup>+</jats:sup>\n levels. Future studies should assess whether a rapid increase in NAD\n <jats:sup>+</jats:sup>\n by parenteral administration can attenuate disease severity and AKI.\n </jats:p>\n <jats:p>\n <jats:bold>Trial Registration:</jats:bold>\n <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link>\n Identifier: NCT05038488\n </jats:p>",
"alternative-id": [
"10.1096/fba.2025-00014"
],
"article-number": "e70011",
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2025-01-16"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "2025-03-31"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 3,
"value": "2025-06-18"
}
],
"author": [
{
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"family": "Pencina",
"given": "Karol M.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Division of Renal Medicine Brigham and Women's Hospital Boston Massachusetts USA"
}
],
"family": "Leaf",
"given": "David E.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"family": "Valderrabano",
"given": "Rodrigo J.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Medicine, Section of Nephrology Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA"
}
],
"family": "Waikar",
"given": "Sushrut S.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Family and Community Medicine University of Alabama Birmingham Alabama USA"
}
],
"family": "Mehta",
"given": "Tapan S.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"family": "Shang",
"given": "Yili Valentine",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"family": "Latham",
"given": "Nancy K.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Family and Community Medicine University of Alabama Birmingham Alabama USA"
}
],
"family": "John",
"given": "Tejossy",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "University of Texas Medical Branch Galveston Texas USA"
}
],
"family": "Volpi",
"given": "Elena",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Tulane University School of Medicine New Orleans Louisiana USA"
}
],
"family": "Fusco",
"given": "Dahlene",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"family": "Memish‐Beleva",
"given": "Yusnie",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Renal Medicine Brigham and Women's Hospital Boston Massachusetts USA"
}
],
"family": "Krishnamurthy",
"given": "Shobana",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Metro International Biotech Worcester Massachusetts USA"
}
],
"family": "Lavu",
"given": "Siva",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Metro International Biotech Worcester Massachusetts USA"
}
],
"family": "Karmi",
"given": "Salma",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Metro International Biotech Worcester Massachusetts USA"
}
],
"family": "Livingston",
"given": "David J.",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0002-3982-6200",
"affiliation": [
{
"name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA"
}
],
"authenticated-orcid": false,
"family": "Bhasin",
"given": "Shalender",
"sequence": "additional"
}
],
"container-title": "FASEB BioAdvances",
"container-title-short": "FASEB BioAdvances",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"faseb.onlinelibrary.wiley.com"
]
},
"created": {
"date-parts": [
[
2025,
6,
19
]
],
"date-time": "2025-06-19T00:45:49Z",
"timestamp": 1750293949000
},
"deposited": {
"date-parts": [
[
2025,
10,
28
]
],
"date-time": "2025-10-28T15:37:59Z",
"timestamp": 1761665879000
},
"indexed": {
"date-parts": [
[
2025,
10,
28
]
],
"date-time": "2025-10-28T15:46:16Z",
"timestamp": 1761666376303,
"version": "build-2065373602"
},
"is-referenced-by-count": 0,
"issue": "8",
"issued": {
"date-parts": [
[
2025,
6,
18
]
]
},
"journal-issue": {
"issue": "8",
"published-print": {
"date-parts": [
[
2025,
8
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2025,
6,
18
]
],
"date-time": "2025-06-18T00:00:00Z",
"timestamp": 1750204800000
}
}
],
"link": [
{
"URL": "https://faseb.onlinelibrary.wiley.com/doi/pdf/10.1096/fba.2025-00014",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "311",
"original-title": [],
"prefix": "10.1096",
"published": {
"date-parts": [
[
2025,
6,
18
]
]
},
"published-online": {
"date-parts": [
[
2025,
6,
18
]
]
},
"published-print": {
"date-parts": [
[
2025,
8
]
]
},
"publisher": "Wiley",
"reference": [
{
"DOI": "10.1016/S0140-6736(20)31189-2",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_2_1"
},
{
"DOI": "10.1001/jama.2020.2648",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_3_1"
},
{
"DOI": "10.1056/NEJMoa2004500",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_4_1"
},
{
"key": "e_1_2_10_5_1",
"unstructured": "350(c)(1)(B). USCU “Guidance for Clinical Investigators Sponsors and IRBs—Investigational New Drug Applications (INDs)—Determining Whether Human Research Studies Can Be Conducted Without an IND September 2013 (Final Guidance)”."
},
{
"DOI": "10.1172/JCI137647",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_6_1"
},
{
"DOI": "10.1016/S0140‐6736(20)30628‐0",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_7_1"
},
{
"DOI": "10.1093/cid/ciaa248",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_8_1"
},
{
"DOI": "10.1038/cmi.2015.74",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_9_1"
},
{
"DOI": "10.3389/fimmu.2015.00361",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_10_1"
},
{
"DOI": "10.1016/S0140-6736(23)00510-X",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_11_1"
},
{
"DOI": "10.1016/S0140-6736(21)00676-0",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_12_1"
},
{
"DOI": "10.1001/jama.2021.11330",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_13_1"
},
{
"article-title": "Janus Kinase Inhibitors for the Treatment of COVID‐19",
"author": "Kramer A.",
"issue": "6",
"journal-title": "Cochrane Database of Systematic Reviews",
"key": "e_1_2_10_14_1",
"volume": "6",
"year": "2022"
},
{
"DOI": "10.1016/j.it.2022.02.001",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_15_1"
},
{
"DOI": "10.1074/jbc.RA120.015138",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_16_1"
},
{
"DOI": "10.1111/acel.14326",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_17_1"
},
{
"DOI": "10.1038/ncomms12948",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_18_1"
},
{
"DOI": "10.1210/clinem/dgad027",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_19_1"
},
{
"DOI": "10.1093/gerona/glac049",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_20_1"
},
{
"DOI": "10.1038/s41467-018-03421-7",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_21_1"
},
{
"DOI": "10.1371/journal.pone.0186459",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_22_1"
},
{
"DOI": "10.1042/BSR20150247",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_23_1"
},
{
"DOI": "10.1038/s41598-019-46120-z",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_24_1"
},
{
"DOI": "10.1002/hep.32778",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_25_1"
},
{
"DOI": "10.1038/s41514-017-0016-9",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_26_1"
},
{
"DOI": "10.1093/ajcn/nqy132",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_27_1"
},
{
"DOI": "10.1126/science.abe9985",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_28_1"
},
{
"DOI": "10.1038/s41598-017-03418-0",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_29_1"
},
{
"DOI": "10.1016/j.bbamcr.2013.04.005",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_30_1"
},
{
"DOI": "10.3389/fimmu.2023.1158455",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_31_1"
},
{
"DOI": "10.1038/s41591-018-0138-z",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_32_1"
},
{
"DOI": "10.34067/KID.0006452020",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_33_1"
},
{
"article-title": "Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals",
"author": "Kimura S.",
"issue": "9",
"journal-title": "Cureus",
"key": "e_1_2_10_34_1",
"volume": "14",
"year": "2022"
},
{
"DOI": "10.1002/advs.202101222",
"doi-asserted-by": "publisher",
"key": "e_1_2_10_35_1"
}
],
"reference-count": 34,
"references-count": 34,
"relation": {},
"resource": {
"primary": {
"URL": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fba.2025-00014"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Oral\n <scp>MIB</scp>\n ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With\n <scp>COVID</scp>\n ‐19 and Acute Kidney Injury: A Randomized Controlled Trial",
"type": "journal-article",
"update-policy": "https://doi.org/10.1002/crossmark_policy",
"volume": "7"
}